LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 3 von insgesamt 3

Suchoptionen

  1. Artikel ; Online: Ocular Surface Disease and Anti-Glaucoma Medications: Various features, Diagnosis, and Management Guidelines.

    Andole, Sowmya / Senthil, Sirisha

    Seminars in ophthalmology

    2022  Band 38, Heft 2, Seite(n) 158–166

    Abstract: Purpose: Assessment of ocular surface in patients using anti-glaucoma medications (AGM) is rarely a priority for clinicians since glaucoma management targets intraocular pressure and preserves vision. This review summarizes the various adverse effects ... ...

    Abstract Purpose: Assessment of ocular surface in patients using anti-glaucoma medications (AGM) is rarely a priority for clinicians since glaucoma management targets intraocular pressure and preserves vision. This review summarizes the various adverse effects of topical AGM on the ocular surface and highlights the importance of ocular surface assessment in these patients.
    Methods: A literature search of articles (English only) on the subject matter was conducted focusing on recent articles published in the past 5 years.
    Results: The use of multiple anti-glaucoma medications in glaucoma patients increases patients' exposure to the drug and the preservatives present in these medications. Long-term use of these medications has deleterious effects on the conjunctiva, cornea, eyelids, and periocular tissues like trichiasis, entropion, symblepharon, forniceal shortening, punctate keratopathy, non-healing epithelial defects, and pannus. Treatment requires drug withdrawal or substitution by oral or topical non-preserved and less toxic preparations of AGMs. The ocular surface and symptoms can improve if the condition is diagnosed early and after drug withdrawal in over 90% of eyes. However, stopping or changing AGMs can often present with its own unique set of challenges in intra-ocular pressure control which may often need glaucoma surgery in close to 20% of eyes for IOP control.
    Conclusion: Topical antiglaucoma medications (with their preservatives) can induce severe ocular surface and periorbital changes. Early identification and withdrawal of the offending drug/preservative can help to reverse the changes except in eyes with extensive cicatrization.
    Mesh-Begriff(e) Humans ; Antiglaucoma Agents ; Antihypertensive Agents/adverse effects ; Glaucoma/diagnosis ; Glaucoma/drug therapy ; Intraocular Pressure ; Eyelids ; Preservatives, Pharmaceutical/adverse effects
    Chemische Substanzen Antiglaucoma Agents ; Antihypertensive Agents ; Preservatives, Pharmaceutical
    Sprache Englisch
    Erscheinungsdatum 2022-08-01
    Erscheinungsland England
    Dokumenttyp Review ; Journal Article
    ZDB-ID 632820-9
    ISSN 1744-5205 ; 0882-0538
    ISSN (online) 1744-5205
    ISSN 0882-0538
    DOI 10.1080/08820538.2022.2094714
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 2153: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: Field-based 3D-QSAR for tyrosine protein kinase JAK-2 inhibitors.

    Andole, Sowmya / Thumma, Gouthami / Alavala, Rajasekhar Reddy / Gangarapu, Kiran

    Journal of biomolecular structure & dynamics

    2023  Band 42, Heft 10, Seite(n) 5321–5333

    Abstract: The present work aimed to develop a Field-based 3D-QSAR model with existing JAK-2 inhibitors. The JAK-STAT pathway is known to play a role in the development of autoimmune diseases, including rheumatoid arthritis, ulcerative colitis, and Crohn's disease. ...

    Abstract The present work aimed to develop a Field-based 3D-QSAR model with existing JAK-2 inhibitors. The JAK-STAT pathway is known to play a role in the development of autoimmune diseases, including rheumatoid arthritis, ulcerative colitis, and Crohn's disease. Dysregulation of JAK-STAT is also linked to the development of myelofibrosis and other myeloproliferative diseases. JAK antagonists can be used in many areas of medicine. There are many compounds that already show inhibition of Jak-2. We have developed a Field-based 3D QSAR model which showed good correlation values (
    Mesh-Begriff(e) Quantitative Structure-Activity Relationship ; Janus Kinase 2/antagonists & inhibitors ; Janus Kinase 2/chemistry ; Janus Kinase 2/metabolism ; Protein Kinase Inhibitors/chemistry ; Protein Kinase Inhibitors/pharmacology ; Molecular Docking Simulation ; Molecular Dynamics Simulation ; Humans ; Ligands ; Protein Binding ; Hydrophobic and Hydrophilic Interactions ; Models, Molecular ; Binding Sites ; Drug Design
    Sprache Englisch
    Erscheinungsdatum 2023-07-06
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 49157-3
    ISSN 1538-0254 ; 0739-1102
    ISSN (online) 1538-0254
    ISSN 0739-1102
    DOI 10.1080/07391102.2023.2226723
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 2093: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel: 3D QSAR based Virtual Screening of Flavonoids as Acetylcholinesterase Inhibitors.

    Andole, Sowmya / Sd, Husna / Sudhula, Srija / Vislavath, Lavanya / Boyina, Hemanth Kumar / Gangarapu, Kiran / Bakshi, Vasudha / Devarakonda, Krishna Prasad

    Advances in experimental medicine and biology

    2023  Band 1424, Seite(n) 233–240

    Abstract: In an attempt to develop therapeutic agents to treat Alzheimer's disease, a series of flavonoid analogues were collected, which already had established acetylcholinesterase (AChE) enzyme inhibition activity. For each molecule we also collected biological ...

    Abstract In an attempt to develop therapeutic agents to treat Alzheimer's disease, a series of flavonoid analogues were collected, which already had established acetylcholinesterase (AChE) enzyme inhibition activity. For each molecule we also collected biological activity data (Ki). Then, 3D-QSAR (quantitative structure-activity relationship model) was developed which showed acceptable predictive and descriptive capability as represented by standard statistical parameters r2 and q2. This SAR data can explain the key descriptors which can be related to AChE inhibitory activity. Using the QSAR model, pharmacophores were developed based on which, virtual screening was done and a dataset was obtained which loaded as a prediction set to fit the developed QSAR model. Top 10 compounds fitting the QSAR model were subjected to molecular docking. CHEMBL1718051 was found to be the lead compound. This study is offering an example of a computationally-driven tool for prioritisation and discovery of probable AChE inhibitors. Further, in vivo and in vitro testing will show its therapeutic potential.
    Mesh-Begriff(e) Cholinesterase Inhibitors/pharmacology ; Cholinesterase Inhibitors/therapeutic use ; Quantitative Structure-Activity Relationship ; Flavonoids/pharmacology ; Molecular Docking Simulation ; Acetylcholinesterase/metabolism
    Chemische Substanzen Cholinesterase Inhibitors ; Flavonoids ; Acetylcholinesterase (EC 3.1.1.7)
    Sprache Englisch
    Erscheinungsdatum 2023-07-24
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 410187-X
    ISSN 0065-2598
    ISSN 0065-2598
    DOI 10.1007/978-3-031-31982-2_26
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 3192: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Einzelsignatur: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang